Teva Generics leads the US generic pharmaceutical market in total and new prescriptions, with total prescriptions of approximately 500 million in 2014.
Teva Generics leads the US generic pharmaceutical market in total and new prescriptions, with total prescriptions of approximately 500 million in 2014, representing 14.2% of total US generic prescriptions or 1 out of every 7 generic prescriptions filled in the United States.*
Teva Generics is a division of Teva Pharmaceuticals USA, a wholly owned subsidiary of Israeli-based Teva Pharma- ceutical Industries Ltd., the global leader in generics and one of the top 10 pharmaceutical companies in the world. Teva’s extensive US operations are headquartered outside of Philadelphia, Pennsylvania. Approximately 45% of the company’s generic revenue is generated in the United States.
Teva’s primary competitive advantages are its ability to continually introduce new and complex generic equivalents for brand-name drug products on a timely basis; its quality, customer service, and the breadth of its product portfolio. Teva markets the broadest product line in the industry, with approximately 375 generic products in more than 1100 dosage strengths and package sizes, covering all major therapeutic categories. In combination with its portfolio, Teva’s global network capabilities have provided mutual strategic advantages to its customers.
The company aggressively pursues new research and development efforts to make better health care accessible to patients. As of January 22, 2015, Teva had 120 abbreviated new drug applications pending FDA approval and introduced over 20 generic products in the United States in 2014.